Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $40.5 million.

  • Lineage Cell Therapeutics' Cash & Current Investments rose 2376.88% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 2376.88%. This contributed to the annual value of $47.8 million for FY2024, which is 3469.23% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Cash & Current Investments of $40.5 million as of Q3 2025, which was up 2376.88% from $42.3 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash & Current Investments peaked at $97.1 million during Q4 2022, and registered a low of $32.7 million during Q3 2024.
  • For the 5-year period, Lineage Cell Therapeutics' Cash & Current Investments averaged around $54.4 million, with its median value being $47.8 million (2024).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 23946.97% in 2021, then crashed by 6346.38% in 2023.
  • Lineage Cell Therapeutics' Cash & Current Investments (Quarter) stood at $58.4 million in 2021, then soared by 66.46% to $97.1 million in 2022, then plummeted by 63.46% to $35.5 million in 2023, then skyrocketed by 34.69% to $47.8 million in 2024, then dropped by 15.31% to $40.5 million in 2025.
  • Its Cash & Current Investments stands at $40.5 million for Q3 2025, versus $42.3 million for Q2 2025 and $47.9 million for Q1 2025.